PHARMAMAR FACES HURDLES BRINGING LURBINECTEDIN ( ZEPZELCA ) TO EUROPEAN PATIENTS .////. PHARMAMAR SE ENFRENTA A OBSTÁCULOS PARA LLEVAR LURBINECTEDIN ( ZEPZELCA ) A LOS PACIENTES EUROPEOS .

 

PharmaMar also points to the bigger picture . 

The company employs more than 450 people . 

It invests in clinical trials and exports up to 95% of its production .

That brings tax revenue and foreign currency into Spain . 

“If you look at the fiscal balance, it is worth it if our value is recognized,” Mora said .

He praised Spain’s strong clinical trial and hospital network . 

But approval does not always mean access .

 The Haute Autorité de Santé in France has denied early access or reimbursement for ZEPZELCA in combination with atezolizumab for patients without CNS metastases .

 NATIONAL HEALTH AUTHORITIES CAN STILL SAY NO .